Royalty Pharma Plc (RPRX) Stock Price, Financials & Summary

Price chart

Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23

Key dataOct 23, 2026

Open$63.50

From 52W high−0.74%

Volume430185.00

Market cap$28.27B

P/E (TTM)26.3x

P/S (TTM)11.1x

Div yield1.46%

Key dataOct 23, 2026

Open

$63.50

From 52W high

−0.74%

Volume

430185.00

Market cap

$28.27B

ValuationView details →

P/E (Fwd)

12.6x

EV/EBITDA

22.9x

P/E (TTM)

26.3x

RSI (14)

68.6

MomentumView details →

1D Return

−0.41%

YTD Return

+63.54%

SummaryUpdated Jun 1, 2026

Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties and funder of innovation in the healthcare industry. Founded in 1996 and based in New York, the company went public in June 2020. Royalty Pharma operates as a specialized investment firm that acquires royalty streams from successful pharmaceutical and biotechnology products, providing capital to innovators while generating returns for shareholders through predictable cash flows from marketed therapies and development-stage products.

Ask drillr about Royalty Pharma Plc →

ValuationView details →

P/E (Fwd)

12.6x

P/E (TTM)

26.3x

EV/EBITDA

22.9x

EV/Sales

15.5x

P/S (TTM)

11.1x

P/B (TTM)

4.1x

ProfitabilityView details →

Gross Margin

89.38%

Net Margin

32.15%

EBITDA Margin

67.66%

ROE (TTM)

11.93%

ROA (TTM)

4.11%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

+10.01%

EPS YoY

+3.27%

FCF YoY

+23.70%

Revenue CAGR 3Y

+2.06%

EPS CAGR 3Y

+187.74%

EBITDA YoY

−11.14%

MomentumView details →

1D Return

−0.41%

YTD Return

+63.54%

1Y Return

+71.48%

RSI (14)

68.6

vs 50D SMA

+6.02%

vs 200D SMA

+20.42%

Capital & dividendView details →

Debt/Equity

1.31x

Current Ratio

1.29x

Quick Ratio

1.29x

Div Yield

1.46%

Div Rate

$0.92

Div Growth 1Y

+4.76%

EarningsView details →

EPS (Actual)

$1.32

EPS Surprise

3.94%

Beats (12Q)

8/12

Next Q EPS Est

$1.52

Avg Surprise (4Q)

9.49%

Rev Surprise

1.85%

Financials snapshotView financials →

Revenue (TTM)

2.54B

Net Income (TTM)

815.30M

Op. CF (TTM)

2.98B

Next earningsNov 4, 2026 →

Latest newsMore news →

Royalty Pharma plc approved a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share.7d ago

Royalty Pharma announced that it will report its third-quarter 2026 financial results on November 4, 2026, before U.S. markets open, and host a conference call and webcast at 8:00 a.m. Eastern Time.14d ago

Similar companies

Shanghai Henlius Biotech, Inc.02696.HK Simcere Pharmaceutical Group Limited02096.HK Roivant Sciences Ltd.ROIV Alnylam Pharmaceuticals, Inc.ALNY 泽璟制药-U688266.SH United Therapeutics CorporationUTHR Find similar companies →

Latest newsMore news →

Royalty Pharma plc approved a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share.7d ago Royalty Pharma announced that it will report its third-quarter 2026 financial results on November 4, 2026, before U.S. markets open, and host a conference call and webcast at 8:00 a.m. Eastern Time.14d ago